What is PTT2.0?
The purpose of the PTT2.0 study is the collection of research data to improve our knowledge on genetic alterations in relapsed and progressive childhood tumors.
The data collected here will enable the development of new treatment strategies for patients, individualized cancer therapy and risk stratification in the future. This study has been reviewed and approved by the ethics committee of the Medical Faculty of the University of Heidelberg.
What are the goals of the PTT2.0 study?
It is widely accepted that cancer is a disease resulting from genetic and epigenetic changes (i.e. changes in factors controlling genetic information) in the cells that make up the body. In this study, researchers are trying to understand these specific genetic and epigenetic changes in tumors, and are looking for changes that can be exploited for targeted therapies (which selectively interfere with the specific changes in a tumor, as opposed to chemotherapy).
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We suppose that in the near future, the tumor and the blood of all cancer patients will be analyzed in such a manner, in order to treat each patient as individually as possible.
In order to be prepared for this new era, and also to benefit today from these technical possibilities at least in part, we introduce these analyses in the PTT2.0 study. Our goal is to achieve a turnaround time of 4 weeks for the analysis of the genetic information and clinical evaluation of the changes discovered. At the same time we want to collect data on possible therapies and how to implement them.
The decision about if and which kind of therapy is given to you based on the genetic analysis, lies solely with your treating physician. The targets identified by the genetic analysis can be used by your treating physician for his decision.
We want to document your clinical course, irrespective of which treatment you receive, in order to compare the application of targeted therapies to standard chemotherapies, as well as to compare the actionability of the different targets found. By collecting this data, we hope to: a) learn more about the genetic structure of pediatric tumors, b) identify common and actionable targets c) and identify most promising therapeutic strategies.
Why were you selected?
You were selected because you were diagnosed with cancer refractory to standard of care treatment. Therefore, the genetic information of your tumor obtained via PTT2.0 might be used to select novel therapeutic approaches. The consent to participate is voluntary and can be withdrawn at any time without reason, which will bear no disadvantages for you.
What does the participation include?
Your participation in the PTT2.0 study requires the consent to participate in the following three points: analyze your blood, approx. 5ml (corresponding to approx. 1 tea spoon) for this study. The blood will be gained during routine blood sampling. The genetic information (DNA) from the blood will be extracted. The DNA will be used for targeted sequencing, which is a process that will allow us to identify many changes unique to you, which distinguish your DNA from the DNA of other people. We need this information in order to identify changes in the tumor, which are not detectable in normal tissue.
C. Clinical Data:
Your consent to participate will allow us to collect relevant information on your health and disease in this study. This information can be collected e.g. from hospital files, and can be send from your treating hospital directly to us.
How will the data and samples be stored and protected?
All your collected tissue and blood samples will be analyzed during routine diagnostics. All doctors and scientists working with these samples are bound to data protection. All samples will be sent back to the submitting institution after completion of diagnostics and validation. Your data as well as all results from the analyses are stored in a protected database at the German Cancer
Research Center (DKFZ), and stored for at least 10 years after the end of this study.
Who is allowed to use the data of your child?
One of the goals of the PTT2.0 study is to share anonymized data with other researchers (national and international academic researchers), in order to facilitate and accelerate the investigation of the causes and potential therapies of cancer. However, the PTT2.0 study group also respects the individuals providing their samples for this project, and will ensure their privacy. To achieve this, all personal identifiers, such as your name or address will be removed, and replaced by a unique identifier (pseudonymization). Pseudonymization means that a code consisting of numbers and/or letters will be used, possibly in combination with the year of birth (but not the complete date of birth). Only the PTT2.0 study group will be able to connect this code with information that can be used to identify you. The coded data will be stored in two separate databases, public databases and databases with controlled access.
• Public databases: Information from this databases is publically available, but
can not be used to identify you specifically. Only data on e.g. kind of tumor, age group, tumor specific mutations can be found here.
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• Databases with controlled access: The data will only be accessible to researchers, and only be used for the study of causes of and therapeutic options for cancer.
All results from research based on data from the PTT2.0 study can be used for teaching, research, and publication including presentation at e.g. research meetings. In all cases of publication your identity remains confidential.
What is the benefit of your participation?
The biggest health-related benefit of the PTT2.0 study will only be accessible in a few years, and as such only the next patient generation will fully benefit from the results. However, should we detect changes in your genetic information, which could inform your current treatment, this information can be used by your treating physician.
What are the risks for you?
Physical risks: since we only use tissues and blood samples, that are collected during routine procedures that are conducted for diagnostic purposes independent of this study, there are practically no risks for you. The storage of the tissue and blood samples poses only a minimal risk, since a high level of security measures are taken to protect stored specimens from unauthorized access at the German Cancer Research Center (DKFZ), the University Hospital Heidelberg, and the National Center of Tumor diseases (NCT).
Protection of privacy: There is a minimal risk, that genetic information generated in the PTT2.0 study can be connected to genetic or medical information from other databases. It is theoretically possible, however very unlikely, that security measures used to protect the data stored in the data bases, are broken. Of course no employer, insurance agency, or non-authorized family members will get access to this data.
What happens if something is detected in my tumor or in my normal tissue?
A. Information that can be used for diagnostics and therapy
As described under (7), your treating physician has access to the results of the PTT2.0 study. Therefore you can gain access to the data through your treating physician, if the analyses reveal a clear clinical benefit concerning the treatment of your tumor disease. The molecular genetic data may only be used for therapeutic purposes. We can only evaluate the clinical benefit once at the time of analysis, not over and over. In this respect, we cannot guarantee an access to the data, if the changing scientific consensus indicates a clinical benefit.
B. Signs of heritable disease:
If the clinically usable information possibly concerns other family members (e.g.
heritable susceptibility for (other) cancer diseases, such as breast or colon cancer), and you have consented to be informed about such a result, these results will be communicated to you in a human genetics counselling session.
This only applies if you have explicitly consented to this procedure.
In the unlikely event that potential risk factors for other diseases, not related to the tumor disease, are found in the DNA, these will not be communicated to you. 
Will you be paid for participation?
Participation is on a strictly voluntary basis, no payments are made.
How can you withdraw your consent to participate in the study?
You can withdraw your consent to participate in the PTT2.0 study at any time without need for giving a reason. Please inform your treating physician.
If you withdraw your consent, your remaining samples will be destroyed. Data that have already been generated as well as collected clinical data cannot be withdrawn, however no new information will be added to the PTT2.0 database.
Your identifiers, such as name, address, complete date of birth, will be deleted.
If the data have already been added to a different database, a connection of the data to you will not be possible anymore.
What can you do in case of second thoughts?
If you first decide to participate in this study, and have second thoughts in the 
